French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced late Wednesday that it has received US Food and Drug Administration (FDA) approval for Infilbray (venglustat), an oral medicine for treating neurological manifestations of Type 3 Gaucher disease (GD3) in adults and children weighing at least 15 kg.
The once-daily glucosylceramide synthase inhibitor is designed to cross the blood-brain barrier and address neurological complications associated with the rare genetic disorder.
This approval is supported by positive results from the Phase 3 LEAP2MONO study, which demonstrated statistically significant superiority over enzyme replacement therapy imiglucerase across multiple neurological endpoints. Patients receiving Infilbray showed improvements in cognitive function, coordination and balance after 52 weeks of treatment.
Infilbray has received breakthrough therapy, rare paediatric disease and fast-track designations in the US, alongside orphan drug designations in the US, EU and Japan. Sanofi is pursuing further regulatory approvals, with applications planned across additional markets in 2026 and 2027. The medicine remains under regulatory review in the EU, Japan and other jurisdictions.
Apotex launches generic version of INLYTA in US market
Genentech secures first FDA approval for primary membranous nephropathy treatment
ViiV Healthcare receives positive EU recommendation for expanded paediatric HIV treatments
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Sunnyside adds GLP-1 options to its medication program for Alcohol Use Disorder
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
Ascletis announces submission of US IND application for oral obesity combination therapy
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels